drug aducanumab supposed drug finally proved idea multiple failures biogen eisai believed aducanumab potent better job removing beta amyloid enrolled patients trials early signs alzheimer disease belief improve chances success not disappointing news confirms complexity treating alzheimer disease need advance knowledge neuroscience incredibly grateful alzheimer disease patients families investigators participated trials contributed greatly research biogen ceo michel vounatsos said statement biogen bet heavily aducanumab resisting calls investors diversify meaningful way protect ultra risky alzheimer endeavor aducanumab failed biogen recover future growth come uncomfortable questions company face days ahead uncontroversial biogen growth problem wrote paul matteis analyst stifel note investors said